WebJan 22, 2024 · Editas said Cynthia Collins, currently an Editas board member, will serve as interim CEO during the search for a successor. Judging by the market reaction, investors … Web2 days ago · Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today ...
First 90 Days: Editas Medicine’s Gilmore O’Neill PharmaVoice
WebApr 13, 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1. Ms. WebJan 9, 2024 · Editas Medicine will continue advancing its cellular therapy assets through partnerships, including continued development of alpha-beta T-cell medicines with Bristol-Myers-Squibb and gamma-delta T ... hemingway\\u0026johnsonville buy or sell
Editas Medicine Announces Second Quarter 2024 Results and …
Web18 hours ago · For their last quarter, Editas Medicine (EDIT) reported earnings of -$0.88 per share, missing the Zacks Consensus Estimate of -$0.84 per share. This reflects a negative … WebApr 13, 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director ... Web2 days ago · Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. landscapers irish terrier